David A Margolis
Overview
Explore the profile of David A Margolis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
2009
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gumm A, Chan A, Margolis D, Gries M, Lerret S
Prog Transplant
. 2021 Oct;
31(4):392-393.
PMID: 34713736
No abstract available.
2.
Mills A, Richmond G, Newman C, Osiyemi O, Cade J, Brinson C, et al.
AIDS
. 2021 Oct;
36(2):195-203.
PMID: 34652287
Objectives: Long-acting formulations of cabotegravir (CAB) and rilpivirine (RPV) have demonstrated efficacy in Phase 3 studies. POLAR (NCT03639311) assessed antiviral activity and safety of CAB+RPV long-acting administered every 2 months...
3.
Jaeger H, Overton E, Richmond G, Rizzardini G, Andrade-Villanueva J, Mngqibisa R, et al.
Lancet HIV
. 2021 Oct;
8(11):e679-e689.
PMID: 34648734
Background: Long-acting cabotegravir and rilpivirine administered monthly or every 2 months might address the challenges associated with daily oral antiretroviral therapy. The ATLAS-2M week 48 results showed non-inferiority of long-acting...
4.
Smith G, Henry W, Podzamczer D, Masia M, Bettacchi C, Arasteh K, et al.
Open Forum Infect Dis
. 2021 Sep;
8(9):ofab439.
PMID: 34557563
Background: In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase 2b study, long-acting (LA) injectable cabotegravir + rilpivirine dosed every 8 weeks (Q8W) or every 4 weeks (Q4W) demonstrated...
5.
Swindells S, Lutz T, Van Zyl L, Porteiro N, Stoll M, Mitha E, et al.
AIDS
. 2021 Jul;
36(2):185-194.
PMID: 34261093
Background: ATLAS (NCT02951052), a phase 3, multicenter, open-label study, demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long-acting dosed every 4 weeks was noninferior at week (W) 48...
6.
Chounta V, Overton E, Mills A, Swindells S, Benn P, Vanveggel S, et al.
Patient
. 2021 May;
14(6):849-862.
PMID: 34056699
Background: Advances in HIV-1 therapeutics have led to the development of a range of daily oral treatment regimens, which share similar high efficacy rates. Consequently, more emphasis is being placed...
7.
Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, et al.
Lancet HIV
. 2021 Apr;
8(4):e185-e196.
PMID: 33794181
Background: There is a need for more convenient, less frequent treatment to help address challenges associated with daily oral HIV treatment in people living with HIV, including stigma, pill burden,...
8.
Cutrell A, Schapiro J, Perno C, Kuritzkes D, Quercia R, Patel P, et al.
AIDS
. 2021 Mar;
35(9):1333-1342.
PMID: 33730748
Objective: Efficacy and safety of long-acting cabotegravir (CAB) and rilpivirine (RPV) dosed intramuscularly every 4 or 8 weeks has been demonstrated in three Phase 3 trials. Here, factors associated with...
9.
Overton E, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et al.
Lancet
. 2020 Dec;
396(10267):1994-2005.
PMID: 33308425
Background: Phase 3 clinical studies showed non-inferiority of long-acting intramuscular cabotegravir and rilpivirine dosed every 4 weeks to oral antiretroviral therapy. Important phase 2 results of every 8 weeks dosing,...
10.
Rizzardini G, Overton E, Orkin C, Swindells S, Arasteh K, Gorgolas Hernandez-Mora M, et al.
J Acquir Immune Defic Syndr
. 2020 Nov;
85(4):498-506.
PMID: 33136751
Background: Long-acting (LA) injectable regimens are a potential therapeutic option in people living with HIV-1. Setting: ATLAS (NCT02951052) and FLAIR (NCT02938520) were 2 randomized, open-label, multicenter, multinational phase 3 studies....